

# Henry Lik Yuen Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6123369/publications.pdf>

Version: 2024-02-01

486  
papers

44,040  
citations

1704

104  
h-index

2828

191  
g-index

488  
all docs

488  
docs citations

488  
times ranked

29520  
citing authors

#	ARTICLE	IF	CITATIONS
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	4.2	1,908
2	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
3	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
4	Hepatitis B virus infection. <i>Lancet</i> , The, 2014, 384, 2053-2063.	13.7	1,233
5	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 454-462.	7.3	1,052
6	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	27.0	945
7	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	4.2	874
8	Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 605-611.	1.6	576
9	Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. <i>New England Journal of Medicine</i> , 2005, 352, 238-244.	27.0	567
10	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1317-25.	7.1	543
11	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , The, 2011, 12, 568-574.	10.7	541
12	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010, 59, 969-974.	12.1	538
13	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. <i>Gut</i> , 2004, 53, 1494-1498.	12.1	455
14	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424
15	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012, 61, 409-415.	12.1	423
16	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	7.3	408
17	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	3.7	398
18	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016, 65, 1359-1368.	12.1	386

#	ARTICLE	IF	CITATIONS
19	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 196-206.	8.1	377
20	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 36-44.	2.0	363
21	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18761-18768.	7.1	363
22	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358
23	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	343
24	Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1067-1077.	3.7	338
25	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 185-195.	8.1	336
26	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1462-1468.	4.4	320
27	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 254-269.	3.7	320
28	Eradication of <i>Helicobacter pylori</i> and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. <i>Lancet, The</i> , 2002, 359, 9-13.	13.7	316
29	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet, The</i> , 2007, 369, 1621-1626.	13.7	297
30	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.4	292
31	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	3.7	291
32	Combination of Tenofovir Disoproxil Fumarate and Peginterferon Î±-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	1.3	284
33	Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	3.7	280
34	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
35	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. <i>Radiology</i> , 2013, 269, 910-918.	7.3	267
36	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	3.7	267

#	ARTICLE	IF	CITATIONS
37	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis â€œ A Longitudinal Study. PLoS ONE, 2013, 8, e62885.	2.5	266
38	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65, 54-64.	7.3	260
39	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. Journal of Hepatology, 2013, 59, 536-542.	3.7	254
40	Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression. Cancer Cell, 2014, 25, 335-349.	16.8	254
41	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology, 2013, 12, 256-262.	1.5	252
42	Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology, 1999, 29, 976-984.	7.3	251
43	A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-Î±2b and Lamivudine with Lamivudine Alone. Annals of Internal Medicine, 2005, 142, 240.	3.9	248
44	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut, 2011, 60, 1721-1727.	12.1	248
45	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. American Journal of Gastroenterology, 2015, 110, 1306-1314.	0.4	240
46	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. Journal of Hepatology, 2014, 60, 339-345.	3.7	227
47	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology, 2010, 52, 1232-1241.	7.3	226
48	The changing epidemiology of liver diseases in the Asiaâ€œPacific region. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 57-73.	17.8	221
49	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut, 2011, 60, 829-836.	12.1	219
50	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScanÂ®. Journal of Hepatology, 2012, 56, 833-839.	3.7	218
51	Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy. Gastroenterology, 2005, 128, 1890-1897.	1.3	207
52	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. Annals of Surgical Oncology, 2015, 22, 4138-4148.	1.5	206
53	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology, 2013, 58, 872-880.	7.3	201
54	Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model. American Journal of Gastroenterology, 2005, 100, 616-623.	0.4	200

#	ARTICLE	IF	CITATIONS
55	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , 2017, 7, 45846.	3.3	199
56	Hepatocellular Carcinoma and Hepatitis B Virus. <i>Seminars in Liver Disease</i> , 2006, 26, 153-161.	3.6	198
57	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , 2009, 58, 111-117.	12.1	198
58	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 1349-1356.	3.7	198
59	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009, 124, 2766-2770.	5.1	197
60	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012, 56, 533-540.	3.7	196
61	Fatty Pancreas, Insulin Resistance, and $\beta$ -Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2014, 109, 589-597.	0.4	194
62	Hepatitis B e antigen-negative chronic hepatitis b in Hong Kong. <i>Hepatology</i> , 2000, 31, 763-768.	7.3	190
63	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	12.1	185
64	Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. <i>Hepatology</i> , 2011, 54, 1591-1599.	7.3	183
65	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1154-1161.	4.4	181
66	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	7.3	177
67	Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir. <i>Annals of Internal Medicine</i> , 2007, 147, 745.	3.9	175
68	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, 361-370.	3.7	173
69	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	1.3	171
70	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1104-1112.	3.7	159
71	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019, 29, 418-427.	5.5	159
72	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	1.3	156

#	ARTICLE	IF	CITATIONS
73	Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment. <i>Gastroenterology</i> , 2013, 144, 933-944.	1.3	155
74	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 56-67.	8.1	152
75	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 667-676.	2.8	152
76	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. <i>Cancer Discovery</i> , 2020, 10, 664-673.	9.4	152
77	Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. <i>Gastroenterology</i> , 2014, 146, 1240-1248.	1.3	151
78	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	2.8	151
79	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015, 62, 182-189.	3.7	147
80	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	4.4	143
81	Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2008, 54, 1528-1536.	3.2	141
82	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10925-E10933.	7.1	140
83	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <sc>NAFLD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
84	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (<sc>NAFLD</sc>) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 447-456.	3.7	132
85	Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , 2002, 97, 406-412.	0.4	131
86	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , 2016, 34, 83-90.	1.6	131
87	High Incidence of Mortality and Recurrent Bleeding in Patients With Helicobacter pylori-Negative Idiopathic Bleeding Ulcers. <i>Gastroenterology</i> , 2009, 137, 525-531.	1.3	128
88	Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1277-1279.	3.9	127
89	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 300-305.	2.8	127
90	Prediction of Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Infection by Serum Proteomic Fingerprinting: A Pilot Study. <i>Clinical Chemistry</i> , 2005, 51, 328-335.	3.2	125

#	ARTICLE	IF	CITATIONS
91	Efficacy of Cap-Assisted Colonoscopy in Comparison With Regular Colonoscopy: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2009, 104, 41-46.	0.4	125
92	<i>PNPLA3</i> gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 139-146.	2.8	125
93	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 236-242.	3.7	122
94	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	12.1	121
95	Comparison of EUS and ERCP in the investigation with suspected biliary obstruction caused by choledocholithiasis: a randomized study. <i>Gastrointestinal Endoscopy</i> , 2008, 67, 660-668.	1.0	119
96	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	4.4	119
97	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117
98	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015, 121, 97-108.	4.1	116
99	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. <i>Gastroenterology</i> , 2019, 156, 1392-1403.e7.	1.3	115
100	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014, 59, 986-995.	7.3	114
101	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 883-893.	3.7	113
102	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	12.1	113
103	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017, 67, 902-908.	3.7	112
104	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1095-1103.	3.7	110
105	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	4.0	110
106	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	3.7	110
107	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 387-396.	3.7	108
108	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 344-352.	3.7	107

#	ARTICLE	IF	CITATIONS
109	Long-term Outcome of Helicobacter pylori in Negative Idiopathic Bleeding Ulcers: A Prospective Cohort Study. <i>Gastroenterology</i> , 2005, 128, 1845-1850.	1.3	105
110	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008, 28, 79-87.	3.9	105
111	Histone Deacetylase HDAC8 Promotes Insulin Resistance and $\beta$ -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 4803-4816.	0.9	105
112	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1002-1007.	2.8	104
113	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2008, 103, ???-???	0.4	101
114	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 754-763.	7.3	101
115	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 1945-1953.	7.3	100
116	Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients. <i>Antiviral Therapy</i> , 2011, 16, 1249-1257.	1.0	100
117	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1323-1331.	3.7	98
118	Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. <i>Hepatology</i> , 2010, 51, 2008-2019.	7.3	96
119	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. <i>Annals of Surgery</i> , 2013, 257, 922-928.	4.2	96
120	PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 532-539.	3.7	95
121	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1391-1396.	2.8	95
122	Survival and Prognostic Indicators in Patients with Hepatitis B Virus-Related Cirrhosis After Onset of Hepatic Decompensation. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 569-572.	2.2	92
123	Epidemiological and Virological Characteristics of 2 Subgroups of Hepatitis B Virus Genotype C. <i>Journal of Infectious Diseases</i> , 2005, 191, 2022-2032.	4.0	92
124	Review article: long-term safety of nucleoside and nucleotide analogues in HBV monoinfected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 16-34.	3.7	92
125	Modelling NAFLD disease burden in four Asian regions 2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	3.7	92
126	Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. <i>Modern Pathology</i> , 2004, 17, 1169-1179.	5.5	89



#	ARTICLE	IF	CITATIONS
127	Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 517-526.	3.7	89
128	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1215-1222.	3.7	88
129	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013, 23, 471-482.	9.6	88
130	Is non- <i>Helicobacter pylori</i> , non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. <i>Gastrointestinal Endoscopy</i> , 2001, 53, 438-442.	1.0	87
131	Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2012, 19, 732-743.	2.0	86
132	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 441-453.	8.1	85
133	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	3.7	84
134	RNA Interference Therapy With ARC520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	7.3	84
135	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.4	83
136	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
137	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	3.7	83
138	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	7.3	83
139	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1726-1731.	2.8	82
140	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	1.0	82
141	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	8.1	82
142	Factors associated with viral breakthrough in lamivudine monotherapy of hepatitis B virus recurrence after liver transplantation. <i>Journal of Medical Virology</i> , 2002, 68, 182-187.	5.0	81
143	Histological progression of non-alcoholic fatty liver disease in Chinese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 407-413.	3.7	81
144	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2014, 59, 1714-1723.	5.8	79

#	ARTICLE	IF	CITATIONS
145	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 793-802.	3.7	79
146	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2005, 41, 1357-1364.	7.3	77
147	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015, 62, 684-693.	7.3	77
148	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	3.7	77
149	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139310.	2.5	77
150	Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. <i>American Journal of Gastroenterology</i> , 2002, 97, 1211-1215.	0.4	75
151	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1361-1366.	4.4	75
152	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	3.9	75
153	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017, 65, 1840-1850.	7.3	74
154	Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2011, 6, e22888.	2.5	73
155	Heme Oxygenase-1 Protects Against Steatohepatitis in Both Cultured Hepatocytes and Mice. <i>Gastroenterology</i> , 2010, 138, 694-704.e1.	1.3	72
156	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2013, 20, e37-46.	2.0	72
157	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	3.7	72
158	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 227-233.	4.4	70
159	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014, 61, 708-709.	3.7	69
160	The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. <i>Journal of Viral Hepatitis</i> , 2002, 9, 424-428.	2.0	68
161	Chronic hepatitis B in Asia: new insights from the past decade. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 131-137.	2.8	68
162	How should we manage patients with non-alcoholic fatty liver disease in 2007?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 801-808.	2.8	67

#	ARTICLE	IF	CITATIONS
163	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.4	67
164	The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1899-1905.	3.7	65
165	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 955-961.	2.8	65
166	Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1179-1186.	2.8	65
167	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 295-302.e3.	4.4	64
168	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	3.7	64
169	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 406-417.	8.1	64
170	Genotype-Specific Genomic Markers Associated with Primary Hepatomas, Based on Complete Genomic Sequencing of Hepatitis B Virus. <i>Journal of Virology</i> , 2008, 82, 3604-3611.	3.4	63
171	A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. <i>Journal of Hepatology</i> , 2015, 62, 1100-1111.	3.7	63
172	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	1.3	63
173	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010, 105, 132-138.	0.4	62
174	Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. <i>Journal of Gastroenterology</i> , 2011, 46, 391-400.	5.1	62
175	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1057-1066.	3.7	61
176	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 197-208.	3.7	61
177	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020, 30, 1144-1153.	5.5	61
178	Genetic polymorphisms of adiponectin and tumor necrosis factor- $\alpha$ and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 914-921.	2.8	60
179	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 730-737.	3.7	60
180	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2018, 32, 37-51.	0.5	60

#	ARTICLE	IF	CITATIONS
181	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018, 64, 1239-1249.	3.2	60
182	Anti-proliferative and pro-apoptotic effects of herbal medicine on hepatic stellate cell. <i>Journal of Ethnopharmacology</i> , 2005, 100, 180-186.	4.1	59
183	Evaluation of Model for End-Stage Liver Disease for Prediction of Mortality in Decompensated Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2006, 101, 1516-1523.	0.4	59
184	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 984-992.	3.7	59
185	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	7.3	59
186	Significant positive association of endotoxemia with histological severity in 237 patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 175-182.	3.7	58
187	Hepatitis B virus reactivation associated with anti-neoplastic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 31-37.	2.8	57
188	Bacterial endotoxin and nonalcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 731-740.	3.7	57
189	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
190	Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. <i>Journal of Medical Virology</i> , 2010, 82, 1494-1500.	5.0	54
191	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	3.7	54
192	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	3.7	54
193	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , 2007, 13, 1228-1235.	2.4	53
194	Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. <i>Gut</i> , 2014, 63, 1793-1804.	12.1	53
195	High-Throughput Quantitative Profiling of Serum N-Glycome by MALDI-TOF Mass Spectrometry and N-Glycomic Fingerprint of Liver Fibrosis. <i>Clinical Chemistry</i> , 2007, 53, 1254-1263.	3.2	52
196	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 783-790.e1.	4.4	52
197	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020, 71, 444-455.	7.3	52
198	Liver Injury Is Common Among Chronic Abusers of Ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1759-1762.e1.	4.4	51

#	ARTICLE	IF	CITATIONS
199	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 199-208.	3.7	51
200	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 411-421.	3.7	51
201	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1481-1489.e5.	4.4	51
202	Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 45-49.	3.7	50
203	Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. <i>Diabetologia</i> , 2006, 49, 1777-1784.	6.3	50
204	Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. <i>World Journal of Gastroenterology</i> , 2003, 9, 2695.	3.3	50
205	Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2008, 80, 591-597.	5.0	49
206	Glucose-regulated Protein 78 Is an Intracellular Antiviral Factor against Hepatitis B Virus. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2582-2594.	3.8	49
207	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 63, 1086-1092.	3.7	49
208	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 538-544.	8.1	49
209	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	3.7	49
210	Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. <i>Liver International</i> , 2004, 24, 611-618.	3.9	48
211	Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 519-528.	3.7	48
212	Multiplex Detection of 60 Hepatitis B Virus Variants by MALDI-TOF Mass Spectrometry. <i>Clinical Chemistry</i> , 2009, 55, 1503-1509.	3.2	48
213	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBsAg seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1326-1335.	3.7	48
214	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1001-1010.	3.7	48
215	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	4.4	48
216	Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. <i>Journal of Viral Hepatitis</i> , 2002, 9, 229-234.	2.0	47

#	ARTICLE	IF	CITATIONS
217	Effect of celecoxib on experimental liver fibrosis in rat. <i>Liver International</i> , 2006, 26, 125-136.	3.9	47
218	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010, 4, 386-395.	4.2	47
219	Meta-analysis: reduction in hepatic events following interferon- $\alpha$ therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1059-1068.	3.7	47
220	Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1737-1744.	3.7	46
221	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1113-1120.	4.4	46
222	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients' characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , 2014, 114, 754-760.	2.5	45
223	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3487-3497.	2.3	45
224	Data Mining on DNA Sequences of Hepatitis B Virus. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2011, 8, 428-440.	3.0	44
225	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1363-1369.	2.8	44
226	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020, 4, 8-20.	4.3	43
227	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1453-1460.e1.	4.4	42
228	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	41
229	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	7.3	41
230	Comparison of Three Different Sensitive Assays for Hepatitis B Virus DNA in Monitoring of Responses to Antiviral Therapy. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3205-3208.	3.9	41
231	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	7.3	41
232	Predictors of Treatment Response in Chronic Hepatitis B. <i>Drugs</i> , 2009, 69, 2167-2177.	10.9	40
233	Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, 556-558.	3.7	40
234	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.4	40

#	ARTICLE	IF	CITATIONS
235	RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. <i>Cancer Letters</i> , 2007, 253, 43-52.	7.2	39
236	Elevated Perioperative Transaminase Level Predicts Intrahepatic Recurrence in Hepatitis B-related Hepatocellular Carcinoma After Curative Hepatectomy. <i>Asian Journal of Surgery</i> , 2008, 31, 41-49.	0.4	39
237	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 802-813.	3.7	39
238	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	12.1	39
239	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 506-514.	2.8	39
240	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018, 67, 1278-1284.	5.8	39
241	Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. <i>Gut</i> , 2007, 56, 991-999.	12.1	38
242	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 891-898.	3.7	38
243	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	1.0	38
244	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	3.4	38
245	Clinical significance of hepatic derangement in severe acute respiratory syndrome. <i>World Journal of Gastroenterology</i> , 2005, 11, 2148.	3.3	38
246	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.4	37
247	An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 8041-8047.	1.6	36
248	Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 315-323.	7.3	36
249	<i>Phyllanthus urinaria</i> ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. <i>Hepatology</i> , 2008, 47, 473-483.	7.3	36
250	COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2008, 374, 175-180.	2.1	35
251	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1842-1848.	2.8	35
252	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 957-966.	3.7	35

#	ARTICLE	IF	CITATIONS
253	52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B. PLoS ONE, 2013, 8, e54279.	2.5	34
254	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. Journal of Hepatology, 2014, 60, 809-815.	3.7	34
255	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. Medicine (United States), 2016, 95, e2702.	1.0	34
256	A new screening strategy for varices by liver and spleen stiffness measurement (<sc>LSSM</sc>) in cirrhotic patients: A randomized trial. Liver International, 2018, 38, 636-644.	3.9	34
257	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monophylaxis. Clinical Transplantation, 2004, 18, 295-300.	1.6	33
258	Transmission of hepatitis B by human bite—Confirmation by detection of virus in saliva and full genome sequencing. Journal of Clinical Virology, 2005, 33, 254-256.	3.1	33
259	Truncated <sc>HBx</sc>-dependent silencing of <sc>CAS2</sc> promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. Journal of Pathology, 2015, 237, 38-49.	4.5	33
260	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. Hepatology, 2019, 70, 971-981.	7.3	33
261	Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis. Journal of Cellular Biochemistry, 2006, 97, 795-812.	2.6	32
262	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis <sc>B</sc>. Journal of Viral Hepatitis, 2014, 21, 825-834.	2.0	32
263	Tenofovir Alafenamide: A Review in Chronic Hepatitis B. Drugs, 2017, 77, 1017-1028.	10.9	32
264	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. Liver International, 2011, 31, 1047-1053.	3.9	31
265	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. Journal of Digestive Diseases, 2016, 17, 538-546.	1.5	31
266	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2016, 43, 145-153.	3.7	30
267	Historical epidemiology of hepatitis C virus in select countries—volume 4. Journal of Viral Hepatitis, 2017, 24, 8-24.	2.0	30
268	Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. Alimentary Pharmacology and Therapeutics, 2002, 16, 251-260.	3.7	29
269	A Cost Comparison of Management of Chronic Hepatitis B and Its Associated Complications in Hong Kong and Singapore. Journal of Clinical Gastroenterology, 2004, 38, S136-S143.	2.2	29
270	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. American Journal of Gastroenterology, 2005, 100, 2205-2211.	0.4	29



#	ARTICLE	IF	CITATIONS
271	Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 571-577.	2.1	29
272	Coronavirus in severe acute respiratory syndrome (SARS). <i>Trends in Molecular Medicine</i> , 2003, 9, 323-325.	6.7	28
273	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , 2005, 13, 175-182.	2.7	28
274	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	2.8	28
275	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	2.8	28
276	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. <i>PLoS ONE</i> , 2015, 10, e0122406.	2.5	28
277	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	4.3	28
278	Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. <i>American Journal of Gastroenterology</i> , 2002, 97, 2629-2633.	0.4	27
279	Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 8-12.	2.8	27
280	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 484-491.	2.8	27
281	A baseline tool for predicting response to peginterferon alfa-2a in HBsAg-positive patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 547-555.	3.7	27
282	Gastrointestinal disease burden and mortality: A public hospital-based study from 2005 to 2014. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 124-131.	2.8	27
283	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	12.1	27
284	A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. <i>Biochemical and Biophysical Research Communications</i> , 2008, 374, 773-776.	2.1	26
285	The G1613A Mutation in the HBV Genome Affects HBeAg Expression and Viral Replication through Altered Core Promoter Activity. <i>PLoS ONE</i> , 2011, 6, e21856.	2.5	26
286	Improving transient elastography performance for detecting hepatitis B cirrhosis. <i>Digestive and Liver Disease</i> , 2012, 44, 61-66.	0.9	26
287	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 96-101.	3.7	26
288	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 25-43.	2.0	26

#	ARTICLE	IF	CITATIONS
289	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong's A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	5.8	26
290	Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 323-329.	3.7	25
291	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1399-1406.	3.7	25
292	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.4	25
293	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1022-1026.	4.4	24
294	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	4.4	24
295	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1629-1638.	0.4	24
296	Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 74, 1795-1808.	7.3	24
297	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	7.3	24
298	Phylogenetic, Virological, and Clinical Characteristics of Genotype C Hepatitis B Virus with TCC at Codon 15 of the Precore Region. <i>Journal of Clinical Microbiology</i> , 2006, 44, 681-687.	3.9	23
299	Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 63-69.	2.8	23
300	The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. <i>Liver International</i> , 2009, 29, 25-36.	3.9	23
301	Treatment of non-alcoholic steatohepatitis with <i>hyllanthus urinaria</i> : A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 57-62.	2.8	23
302	The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , 2015, 22, 328-334.	2.0	23
303	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016, 64, 1507-1517.	7.3	23
304	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1213-1224.	3.7	23
305	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 271-279.	3.9	23
306	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	3.7	23

#	ARTICLE	IF	CITATIONS
307	Use of Hepatitis B Virus DNA Quantitation To Predict Hepatitis B e Antigen Reversion in Cases of Chronic Hepatitis B. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4793-4795.	3.9	22
308	Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 783-789.	2.8	22
309	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1830-1836.	3.9	22
310	Identifying Hepatitis B Carriers at Low Risk for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2012, 142, 1057-1060.	1.3	22
311	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1762-1769.	2.8	22
312	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 347-352.	2.2	22
313	Impact of severe acute respiratory syndrome on liver transplantation service. <i>Transplantation Proceedings</i> , 2004, 36, 2302-2303.	0.6	21
314	Retrospective analysis of liver function derangement in severe acute respiratory syndrome. <i>American Journal of Medicine</i> , 2004, 116, 566-567.	1.5	21
315	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: A seven-year follow-up study. <i>Journal of Medical Virology</i> , 2009, 81, 224-229.	5.0	21
316	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	2.9	21
317	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.8	21
318	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	4.4	21
319	Aberrant Concentrations of Liver-Derived Plasma Albumin mRNA in Liver Pathologies. <i>Clinical Chemistry</i> , 2010, 56, 82-89.	3.2	20
320	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 424-431.	3.7	20
321	Metabolic syndrome delays HBsAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 716-726.	3.7	20
322	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014, 65, 174-186.	2.9	20
323	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 43-51.	4.2	20
324	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	2.5	20

#	ARTICLE	IF	CITATIONS
325	Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 3547-3551.	0.4	19
326	Double-blinded placebo-controlled study of <i>Phyllanthus urinaris</i> for the treatment of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 339-345.	3.7	19
327	Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3541-3547.	2.3	19
328	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2210-2219.	2.8	19
329	Changing scene in hepatitis B serology interpretation. <i>British Journal of Hospital Medicine</i> , 2002, 63, 16-19.	0.2	18
330	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	2.3	18
331	Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis. <i>Advances in Therapy</i> , 2016, 33, 862-875.	2.9	18
332	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	4.4	18
333	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	4.9	18
334	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020, 55, 899-908.	5.1	18
335	A magnetic bead-based serum proteomic fingerprinting method for parallel analytical analysis and micropreparative purification. <i>Electrophoresis</i> , 2010, 31, 1721-1730.	2.4	17
336	Individualisation of antiviral therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1206-1216.	2.8	17
337	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	3.0	17
338	Strategies to manage hepatitis C virus infection disease burden—Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 44-63.	2.0	17
339	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	3.9	17
340	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir—A prospective study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 126-135.	2.0	17
341	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	2.0	17
342	High incidence of incidental hepatocellular carcinoma exists among hepatic explanted livers. <i>Transplantation Proceedings</i> , 2003, 35, 350-351.	0.6	16

#	ARTICLE	IF	CITATIONS
343	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 271-278.	3.9	16
344	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	2.8	16
345	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. <i>Hepatology</i> , 2018, 67, 2302-2319.	7.3	16
346	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437.	2.0	16
347	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , 2019, 70, 660-666.	5.8	16
348	Unresolved issues of immune tolerance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 383-389.	5.1	16
349	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	6.1	16
350	Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 71, 329-333.	2.2	15
351	Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1703-1711.	3.7	15
352	Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. <i>Journal of Clinical Virology</i> , 2010, 47, 193-195.	3.1	15
353	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 972-981.	3.7	15
354	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018, 38, 1911-1919.	3.9	15
355	Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 53-59.	2.1	14
356	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 592-598.	2.8	14
357	A complete genomic analysis of hepatitis B virus genotypes and mutations in HBsAg-negative chronic hepatitis B in China. <i>Journal of Viral Hepatitis</i> , 2008, 15, 449-458.	2.0	14
358	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 122-129.	3.6	14
359	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	3.7	14
360	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	2.8	14

#	ARTICLE	IF	CITATIONS
361	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	8.9	14
362	Treatment of chronic hepatitis B: focus on telbivudine. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 259-268.	4.4	13
363	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1641-1647.	2.8	13
364	Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4715-4726.	3.3	13
365	The Molecular Diagnosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 69-101.	6.1	12
366	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Antiviral Therapy</i> , 2013, 18, 979-986.	1.0	12
367	Noninvasive assessments of liver fibrosis with transient elastography and <math>F_{455}</math> index predict survival in patients with chronic hepatitis <math>B</math>. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 582-590.	2.8	12
368	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016, 62, S298-S305.	5.8	12
369	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 228-235.	2.0	12
370	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019, 9, 10529.	3.3	12
371	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	2.2	12
372	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, 5416.	3.3	12
373	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 77-90.	8.9	12
374	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	4.9	12
375	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon $\alpha 2a$ (40 kDa; PEGASYS®). <i>Antiviral Therapy</i> , 2008, 13, 555-562.	1.0	12
376	A review of telbivudine for the management of chronic hepatitis B virus infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1351-1361.	3.3	11
377	Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong. <i>Journal of Hepatology</i> , 2009, 51, 1088-1090.	3.7	11
378	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 377-385.e5.	4.4	11

#	ARTICLE	IF	CITATIONS
379	The safety of stopping nucleos(t)ide analogue treatment in patients with HBsAg-negative chronic hepatitis B. <i>Liver International</i> , 2020, 40, 549-557.	3.9	11
380	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1967-1973.	4.0	11
381	Treatment of Chronic Hepatitis B in Asia-Pacific Countries: Is the Asia-Pacific Consensus Statement being followed?. <i>Antiviral Therapy</i> , 2010, 15, 607-616.	1.0	10
382	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	2.8	10
383	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab205.	0.9	10
384	Performance evaluation of the Elecsys $\alpha$ -fetoprotein (AFP) and Elecsys PIVKA-II assays for hepatocellular carcinoma diagnosis. <i>JGH Open</i> , 2022, 6, 292-300.	1.6	10
385	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	1.0	9
386	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. <i>Hepatology</i> , 2021, 73, 1652-1670.	7.3	9
387	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	2.5	9
388	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	4.3	9
389	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2021, 67, 1492-1502.	3.2	9
390	Fulminant hepatic failure in a patient with inactive HBsAg carrier state, acute hepatitis E and thyrotoxicosis. <i>Hepatology Research</i> , 2003, 27, 248-251.	3.4	8
391	Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B. <i>American Journal of Medicine</i> , 2003, 115, 334-336.	1.5	8
392	Molecular virology in chronic hepatitis B: genotypes. <i>British Journal of Hospital Medicine (London)</i> , 2010, 10, 10-15.	0.5	8
393	Revisiting the treatment recommendations for chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 700-700.	7.3	8
394	Antiviral Therapy for Acute-on-Chronic Liver Failure in Chronic Hepatitis B: Is It Too Late?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2126-2128.	2.3	8
395	Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine. <i>Antiviral Therapy</i> , 2013, 18, 671-680.	1.0	8
396	Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1306-1316.	3.7	8

#	ARTICLE	IF	CITATIONS
397	Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1153-1166.	3.0	8
398	HBV variants are common in the "immune-tolerant" phase of chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 1061-1070.	2.0	8
399	Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?. Gastroenterology, 2020, 158, 2028-2032.	1.3	8
400	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2202-2209.	2.8	8
401	Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135,395 patients from 2000 to 2017. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3487-3499.	2.8	8
402	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. Digestive Diseases and Sciences, 2012, 57, 221-231.	2.3	7
403	Peginterferon therapy for chronic hepatitis B: one size fits all?. Gut, 2013, 62, 185-187.	12.1	7
404	Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infectious Diseases and Therapy, 2014, 3, 191-202.	4.0	7
405	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1040-1048.	2.8	7
406	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2015, 41, 1190-1199.	3.7	7
407	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1071-1078.	2.8	6
408	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS ONE, 2018, 13, e0199198.	2.5	6
409	Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 501-506.	2.8	6
410	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. BMC Gastroenterology, 2020, 20, 128.	2.0	6
411	Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. Journal of Viral Hepatitis, 2022, 29, 156-170.	2.0	6
412	Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma. Transplantation Proceedings, 2004, 36, 2287-2288.	0.6	5
413	Interferon-induced thyroid dysfunction" not always transient. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 938-940.	2.8	5
414	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. Journal of Medical Virology, 2020, 92, 1206-1213.	5.0	5



#	ARTICLE	IF	CITATIONS
415	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. <i>Seminars in Liver Disease</i> , 2021, 41, 182-190.	3.6	5
416	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. <i>Journal of Medical Virology</i> , 2022, 94, 4440-4448.	5.0	5
417	Can dietetic intervention for obesity ever succeed in real life?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 459-460.	2.8	4
418	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2011, 55, 497.	3.7	4
419	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 419-420.	2.8	4
420	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1485-1493.	2.8	4
421	Treatment of hepatitis C virus infection in patients with CKD. <i>Nature Reviews Nephrology</i> , 2016, 12, 5-6.	9.6	4
422	Monocyte-Derived Hepatocyte-Like Cell Test: A Novel Tool for in vitro Identification of Drug-Induced Liver Injury in Patients with Herbal or Dietary Supplements. <i>Digestion</i> , 2021, 102, 650-653.	2.3	4
423	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1610-1618.	2.8	4
424	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. , 2021, , .		4
425	Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). <i>Antiviral Therapy</i> , 2008, 13, 555-62.	1.0	4
426	Liver transplantation for hepatocellular carcinoma in cirrhotic patients—a single-center experience. <i>Transplantation Proceedings</i> , 2003, 35, 379-380.	0.6	3
427	Complications of liver donation for living related liver transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 2224-2225.	0.6	3
428	Reply:. <i>Hepatology</i> , 2009, 50, 2049-2050.	7.3	3
429	Do we need a histological score to diagnose non-alcoholic steatohepatitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 494-495.	3.7	3
430	Response-guided therapy by hepatitis B surface antigen level for peginterferon therapy: What is next?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 420-421.	2.8	3
431	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , 2019, 39, 494-502.	3.9	3
432	Complex genetic encoding of the hepatitis B virus on-drug persistence. <i>Scientific Reports</i> , 2020, 10, 15574.	3.3	3

#	ARTICLE	IF	CITATIONS
433	Adoptive immune transfer in liver transplantation of HBV-related liver diseases. <i>Hepatology</i> , 2003, 37, 1224-1225.	7.3	2
434	High level virion production and surface antigen expression with 1.5 copies of hepatitis B viral genome. <i>Journal of Virological Methods</i> , 2009, 159, 135-140.	2.1	2
435	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2015, 9, 481-483.	4.2	2
436	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 260-262.	8.1	2
437	Effect of pregnancy on the activity and infectivity of hepatitis B virus in women with chronic hepatitis B infection. <i>Hong Kong Medical Journal</i> , 2015, 21 Suppl 7, S4-7.	0.1	2
438	Immunosuppression with rapid steroid reduction among predominantly HBV liver transplantation recipients: initial experience. <i>Transplantation Proceedings</i> , 2003, 35, 419-420.	0.6	1
439	A cirrhotic patient with fever and abdominal pain in the presence of ascites. <i>British Journal of Hospital Medicine</i> , 2003, 64, 310-310.	0.2	1
440	Response to Drs. Navaneethan and Jayanthi. <i>American Journal of Gastroenterology</i> , 2007, 102, 456-456.	0.4	1
441	Letters to the Editors: Potential pitfalls on the validation of liver stiffness measurement by Fibroscan with histological staging in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 937-938.	3.7	1
442	PWE-293â€¦Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general populationâ€”a randomised controlled trial. <i>Gut</i> , 2012, 61, A417.1-A417.	12.1	1
443	Are we ready to use the hepatitis B surface antigen level to guide peginterferon treatment in HBeAg-negative chronic hepatitis B?. <i>Hepatology International</i> , 2013, 7, 13-15.	4.2	1
444	Commentary: how long does one need to fast before a Fibroscan examination?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 540-541.	3.7	1
445	Editorial: metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B â€” authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 983-983.	3.7	1
446	Reply. <i>Hepatology</i> , 2014, 60, 1797-1798.	7.3	1
447	Reply. <i>Hepatology</i> , 2016, 64, 685-686.	7.3	1
448	Reply. <i>Gastroenterology</i> , 2016, 150, 1255.	1.3	1
449	IDDF2018-ABS-0107â€¦Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). , 2018, , .		1
450	Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Coreâ€”Related Antigen to Predict Cure of Hepatitis B Virus Infection. <i>Hepatology</i> , 2021, 73, 870-870.	7.3	1

#	ARTICLE	IF	CITATIONS
451	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.6	1
452	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021, 4, e352.	1.5	1
453	Icteric flare of chronic hepatitis B in a 95-year old patient. <i>World Journal of Gastroenterology</i> , 2003, 9, 2876.	3.3	1
454	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	3.7	1
455	Virological and histological outcome of a patient with chronic hepatitis B transplanted with liver from hepatitis C virus-positive donor. <i>Transplantation Proceedings</i> , 2003, 35, 423-424.	0.6	0
456	Absence of impact of donor hepatic steatosis and posttransplantation lamivudine resistance in a patient with chronic hepatitis B. <i>Transplantation Proceedings</i> , 2004, 36, 2309-2310.	0.6	0
457	A Randomized Controlled Study Comparing Cap-Assisted Colonoscopy Versus Conventional Colonoscopy: The Final Result. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB88.	1.0	0
458	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010, 59, 277.1-277.	12.1	0
459	606: Maternal HBeAg status and hepatitis B viral activity in HBsAg positive mothers. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, S273.	1.3	0
460	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 298-298.	3.6	0
461	Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1331-1332.	3.7	0
462	Letter: pre- and post-operative anti-viral therapy is important for patients with hepatitis B virus-related hepatocellular carcinoma - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 790-790.	3.7	0
463	Reply. <i>Hepatology</i> , 2016, 64, 1820-1821.	7.3	0
464	Letter: factors determining liver fibrosis - more to come. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 171-172.	3.7	0
465	Reply to: "Serum HBsAg kinetics in clinical prediction". <i>Journal of Hepatology</i> , 2017, 67, 193-194.	3.7	0
466	A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, e44.	4.4	0
467	Hepatitis B virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 237.	2.4	0
468	Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance". <i>Journal of Hepatology</i> , 2018, 68, 208-209.	3.7	0

#	ARTICLE	IF	CITATIONS
469	IDDF2018-ABS-0058...Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b " a territory-wide study of 21,182 subjects. , 2018, , .		0
470	IDDF2018-ABS-0106...Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
471	Editorial: a baseline tool for predicting response to peginterferon alfa"2a in <scp>HB</scp>eAg"positive patients" same score, different outcomes. Author's Reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 876-877.	3.7	0
472	Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter" Journal of Hepatology, 2019, 70, 1304.	3.7	0
473	IDDF2019-ABS-0199...The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0
474	IDDF2019-ABS-0168...Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). , 2019, , .		0
475	IDDF2019-ABS-0169...A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. , 2019, , .		0
476	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page" Journal of Hepatology, 2020, 73, 729-730.	3.7	0
477	Editorial: increasing burden of nonalcoholic fatty liver disease"a call to action. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1430-1432.	3.7	0
478	Debate settled for elevated alanine aminotransferase in hepatitis B?. Lancet Infectious Diseases, The, 2021, 21, 750-751.	9.1	0
479	IDDF2021-ABS-0080...96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
480	IDDF2021-ABS-0122...No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients. , 2021, , .		0
481	Abstract 5134: Histone deacetylase 8 is a novel chromatin modulator in NAFLD-associated hepatocarcinogenesis. , 2014, , .		0
482	IDDF2020-ABS-0060...Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF. , 2020, , .		0
483	IDDF2020-ABS-0061...Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB). , 2020, , .		0
484	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. GastroHep, 2022, 2022, 1-13.	0.6	0
485	Functional significance of hepatitis B virus subgenotype Cs genomic markers. Hong Kong Medical Journal, 2014, 20 Suppl 6, 28-30.	0.1	0
486	Non-invasive algorithm for detecting advanced liver fibrosis in chronic hepatitis B patients. Hong Kong Medical Journal, 2014, 20 Suppl 6, 31.	0.1	0